替格瑞洛治疗ST段抬高型心肌梗死的效果

The effect of Ticagrelor on acute ST-elevation myocardial infraction

目的探讨替格瑞洛治疗ST段抬高型心肌梗死(STEMI)的效果。方法选取2016年1月~2017年1月在我院住院治疗的120例STEMI患者,且接受直接经皮冠状动脉介入治疗(PCI),根据治疗方法分为替格瑞洛组和氯吡格雷组,每组各60例。替格瑞洛组患者使用替格瑞洛,氯吡格雷组患者使用氯吡格雷治疗,观察两组患者PCI术后3个月的主要心血管不良事件(major adverse cardiovascular events,MACE)、出血情况及其他不良反应。结果替格瑞洛组的MACE发生率为3.3%,低于氯吡格雷组的8.3%,差异无统计学意义(P>0.05)。两组患者均无大出血发生,小出血发生率差异无统计学意义(P>0.05)。替格瑞洛组呼吸困难发生率高于氯吡格雷组,差异无统计学意义(P>0.05)。结论高龄STEMI患者口服替格瑞洛有减少心血管事件发生趋势,但不增加出血风险。

Objective To evaluate the effect of Ticagrelor on acute ST-elevation myocardial infraction.Methods 120 patients with STEMI admitted to our hospital from January 2016 to January 2017 were performed primary PCI.According to the difference of treatment methods,the patients were divided into Ticagrelor group and Clopidogrel group.At the third month after procedure,the incidence of bleeding and major adverse cardiovascular events(MACE)between two groups were compared.Results In Ticagrelor group,the incidence of MACE was 3.3%,which was lower than that in the Clopidogrel group(8.3%),but no significant difference was observed between both groups(P>0.05).Additionally,the incidence of bleeding,major without,minor was no significant difference was found between both groups(P>0.05).Conclusion Ticagrelor has a tendency to reduce the incidence of MACE,without the increase of the bleeding incidence,in elderly patients with STEMI.